vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and HUYA Inc. (HUYA). Click either name above to swap in a different company.

HUYA Inc. is the larger business by last-quarter revenue ($237.1M vs $156.4M, roughly 1.5× BIOCRYST PHARMACEUTICALS INC). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 2.5%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

HUYA Inc. is a leading interactive live streaming platform based in China, focused primarily on video game live broadcasting. It also offers esports events, variety entertainment, lifestyle and educational live streams, mainly serving young digital entertainment consumers in the domestic Chinese market.

BCRX vs HUYA — Head-to-Head

Bigger by revenue
HUYA
HUYA
1.5× larger
HUYA
$237.1M
$156.4M
BCRX
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
2.5%
HUYA

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
BCRX
BCRX
HUYA
HUYA
Revenue
$156.4M
$237.1M
Net Profit
$1.3M
Gross Margin
13.4%
Operating Margin
13.6%
-0.8%
Net Margin
0.6%
Revenue YoY
7.5%
Net Profit YoY
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
HUYA
HUYA
Q1 26
$156.4M
Q4 25
$406.6M
Q3 25
$159.4M
$237.1M
Q2 25
$163.4M
$218.8M
Q1 25
$145.5M
$207.9M
Q4 24
$131.5M
Q3 24
$117.1M
$219.1M
Q2 24
$109.3M
$212.1M
Net Profit
BCRX
BCRX
HUYA
HUYA
Q1 26
Q4 25
$245.8M
Q3 25
$12.9M
$1.3M
Q2 25
$5.1M
$-766.0K
Q1 25
$32.0K
$128.0K
Q4 24
$-26.8M
Q3 24
$-14.0M
$3.4M
Q2 24
$-12.7M
$4.1M
Gross Margin
BCRX
BCRX
HUYA
HUYA
Q1 26
Q4 25
97.7%
Q3 25
98.6%
13.4%
Q2 25
98.3%
13.5%
Q1 25
96.9%
12.5%
Q4 24
95.4%
Q3 24
97.3%
13.2%
Q2 24
98.4%
13.9%
Operating Margin
BCRX
BCRX
HUYA
HUYA
Q1 26
13.6%
Q4 25
64.0%
Q3 25
18.6%
-0.8%
Q2 25
18.2%
-1.5%
Q1 25
14.6%
-4.0%
Q4 24
-3.4%
Q3 24
6.6%
-2.1%
Q2 24
8.0%
-1.7%
Net Margin
BCRX
BCRX
HUYA
HUYA
Q1 26
Q4 25
60.5%
Q3 25
8.1%
0.6%
Q2 25
3.1%
-0.4%
Q1 25
0.0%
0.1%
Q4 24
-20.4%
Q3 24
-12.0%
1.5%
Q2 24
-11.6%
1.9%
EPS (diluted)
BCRX
BCRX
HUYA
HUYA
Q1 26
$0.00
Q4 25
$1.13
Q3 25
$0.06
Q2 25
$0.02
Q1 25
$0.00
Q4 24
$-0.13
Q3 24
$-0.07
Q2 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
HUYA
HUYA
Cash + ST InvestmentsLiquidity on hand
$259.0M
$102.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$709.9M
Total Assets
$465.1M
$960.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
HUYA
HUYA
Q1 26
$259.0M
Q4 25
$274.7M
Q3 25
$212.9M
$102.0M
Q2 25
$260.0M
$69.7M
Q1 25
$295.1M
$40.9M
Q4 24
$320.9M
Q3 24
$96.8M
$156.1M
Q2 24
$78.4M
$138.4M
Stockholders' Equity
BCRX
BCRX
HUYA
HUYA
Q1 26
Q4 25
$-119.2M
Q3 25
$-387.9M
$709.9M
Q2 25
$-421.6M
$704.3M
Q1 25
$-451.9M
$711.2M
Q4 24
$-475.9M
Q3 24
$-468.6M
$1.1B
Q2 24
$-475.6M
$1.3B
Total Assets
BCRX
BCRX
HUYA
HUYA
Q1 26
$465.1M
Q4 25
$514.2M
Q3 25
$446.4M
$960.3M
Q2 25
$457.2M
$928.0M
Q1 25
$480.0M
$1.3B
Q4 24
$490.4M
Q3 24
$491.3M
$1.6B
Q2 24
$472.4M
$1.6B

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

HUYA
HUYA

Live streaming$162.5M69%
Game-related services, advertising and others$74.7M31%

Related Comparisons